In 2024, the U.S. Drug Enforcement Administration (DEA) indicated which they intend to reclassify cannabis being a Plan III drug. This rescheduling will identify that cannabis has legitimate clinical purposes and will help open the doorway to investigation on other opportunity therapy takes adva